Separately, SunTrust Banks raised their target price on American Renal Associates from $7.00 to $12.00 and gave the stock a hold rating in a research note on Tuesday, September 10th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. American Renal Associates has a consensus rating of Hold and a consensus target price of $11.25.
NYSE ARA traded down $0.13 during trading hours on Thursday, hitting $9.11. The company had a trading volume of 131,259 shares, compared to its average volume of 203,858. American Renal Associates has a 52 week low of $5.48 and a 52 week high of $17.31. The firm has a 50 day simple moving average of $7.43 and a 200 day simple moving average of $7.20. The company has a debt-to-equity ratio of 8.05, a quick ratio of 0.97 and a current ratio of 1.01. The firm has a market capitalization of $309.45 million, a price-to-earnings ratio of 13.96 and a beta of 2.09.
Hedge funds and other institutional investors have recently modified their holdings of the business. Adams Diversified Equity Fund Inc. boosted its stake in American Renal Associates by 24.7% in the 2nd quarter. Adams Diversified Equity Fund Inc. now owns 22,239 shares of the company’s stock worth $165,000 after purchasing an additional 4,400 shares during the period. JPMorgan Chase & Co. boosted its stake in American Renal Associates by 12.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 763,702 shares of the company’s stock worth $5,323,000 after purchasing an additional 84,361 shares during the period. Strs Ohio boosted its stake in American Renal Associates by 32.0% in the 2nd quarter. Strs Ohio now owns 79,200 shares of the company’s stock worth $589,000 after purchasing an additional 19,200 shares during the period. SG Americas Securities LLC bought a new stake in shares of American Renal Associates during the 2nd quarter valued at about $121,000. Finally, Stone Ridge Asset Management LLC bought a new stake in shares of American Renal Associates during the 2nd quarter valued at about $98,000. Institutional investors and hedge funds own 86.12% of the company’s stock.
About American Renal Associates
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Further Reading: Bond
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.